Which semaglutide products are FDA-approved in the United States? The answer requires specific brand and presentation names, not just the active ingredient. As of October 18, 2026, the principal U.S. semaglutide families include Ozempic injection and tablets and Wegovy injection and tablets, with the distinct Wegovy HD higher-dose injection. Legacy Rybelsus tablets remain relevant to the U.S. approval record and the 2026 marketing transition.
This directory helps readers verify a U.S. approval using Drugs@FDA, labeling and the Orange Book. It is not a pharmacy inventory tracker or a substitute for the FDA-approved prescribing information. A product may have an approval history even when the manufacturer has changed branding or stopped wholesale shipments; an approved brand may also have forms with different FDA indications and age restrictions.
If the practical question is where to obtain a legitimate prescribed medicine, see legal U.S. purchase routes. If a seller claims to offer a generic, foreign brand or compounded replacement, check generic semaglutide status and imported product rules. These categories must not be presented as automatically equivalent to an approved FDA product.
Drugs@FDA contains approved human drug applications and associated decisions, labeling and review history. The Orange Book helps identify approved prescription products and therapeutic-equivalence information. A record can support the identity of a brand, route, strength and approved application; it does not establish that a retail pharmacy has the product on the shelf today.
Approval status also does not prove coverage by a plan or establish whether a patient is a candidate. For payment routes use insurance by indication; for product suitability consult the licensed prescriber and the current label.
The entries below are product-family signposts based on FDA approval history, not a claim of continuous active marketing or availability of every strength. Product-specific application supplements, labeled indications, approved formulations and dates should be checked against the current FDA records.
A prescription must name the correct product and formulation. Do not merge the several entries simply because each contains semaglutide.
| U.S. product identity | Route / presentation | FDA record to inspect | Critical distinction |
|---|---|---|---|
| Ozempic injection | Subcutaneous pens | Ozempic NDA 209637 and labeling | Adult type 2 diabetes and injection-specific labeled uses |
| Ozempic tablets | Oral tablets | Oral semaglutide NDA 213051 and labeling | Distinct formulation and strength range |
| Wegovy standard injection | Weekly subcutaneous presentations | Wegovy injection NDA 215256 | Weight management and injection-specific indications |
| Wegovy tablets | Daily oral tablets | Wegovy oral NDA 218316 | Adult oral labeling differs from injections |
| Wegovy HD | 7.2-mg injection | Wegovy injection supplement, March 2026 | Defined higher-dose adult population |
| Rybelsus legacy tablets | Earlier oral semaglutide tablets | Oral semaglutide NDA 213051 / legacy label | 2026 U.S. shipment phase-out, not an active-buy claim |
Ozempic injection is an FDA-approved prescription semaglutide product for labeled adult type 2 diabetes uses, with additional cardiovascular and kidney-related risk reduction statements tied to the injection label. The Ozempic tablet formulation is a distinct oral product with its own labeling, packaging and indicated contexts; it should not inherit every pen indication automatically.
Use Ozempic brand identity and Ozempic tablets for form-specific discussion. Do not describe either as generally FDA-approved for weight-loss treatment.
Standard Wegovy injection and Wegovy oral tablets have their own FDA-approved indications and directions. Some injection uses, including certain pediatric and noncirrhotic MASH-related contexts, should not be projected onto tablets. The FDA approved Wegovy HD 7.2 mg in March 2026 for weight reduction in defined adult patients, not for automatic use by every Wegovy patient.
See Wegovy brand overview, Wegovy tablets and Wegovy HD. The product and dose in the prescription must match the item dispensed.
Rybelsus was a U.S.-approved oral semaglutide brand for type 2 diabetes. During 2026 its U.S. wholesale shipments were being phased out in connection with the newer Ozempic tablet presentation. That commercial transition does not mean its historical application and labeling immediately disappear from FDA records.
The Rybelsus transition guide explains the distinction between legacy tablets and current oral Ozempic. Do not advertise Rybelsus as readily available or invite a self-directed strength substitution based on an old product listing.
Start with the trade name and precise dosage form shown by the seller. Search Drugs@FDA for the product name or active ingredient, then inspect the application, route, manufacturer or holder, approved strengths and latest relevant FDA label. Check the Orange Book for any generic or therapeutic-equivalence claim; verify the pharmacy separately.
A brand name, National Drug Code listing, pharmacy advertisement or a statement that a factory is inspected by FDA does not by itself prove approval of the offered drug. The pharmacy verification checklist addresses licensed dispensing rather than NDA status.
For oral Ozempic, separate the formulation, naming and commercial stages. The newer oral semaglutide formulation was approved while it was branded Rybelsus in December 2024; the FDA action dated January 30, 2026 authorized the Ozempic tablet branding within oral semaglutide NDA 213051. The U.S. market introduction under the Ozempic name followed in May 2026. None of those dates alone establishes a pharmacy's inventory on a particular day.
Wegovy tablets, conventional Wegovy injections and Wegovy HD have separate presentation and supplement histories. When checking FDA records, capture the actual NDA, the strength and dosage form, the particular approval or labeling action and the date of the current label. A historical approval record may remain visible even when a prior brand is no longer routinely supplied.
A semaglutide brand can have several routes and strengths, and a legacy package may have different milligram numbers from a newer oral formulation. Verify the full approved prescribing information and formulation for the exact prescription, especially when advertisements mention old Rybelsus tablets alongside Ozempic tablets.
Do not perform oral-to-oral or oral-to-injection dose conversion for shopping convenience. Pharmacists and clinicians must follow the applicable product labeling.
At each substantive update, compare Drugs@FDA approval history, the latest relevant FDA-approved labeling, Orange Book product entries, manufacturer distribution notices and published FDA safety communications. Date any new claims about approved indications or marketed status.
A citation to an old NDC, a marketplace photo or a manufacturer press release alone is inadequate proof of current approval plus availability. The directory should preserve dated distinctions instead of silently turning regulatory records into stock statements.
The word generic is not evidence of a particular FDA-approved ANDA, and an FDA-approved branded medicine is not equivalent to an unapproved compounded formulation. Products compounded under applicable exceptions are not FDA-approved and have not undergone the same agency premarket review for safety, quality and effectiveness.
FDA raised specific concerns in 2026 about misleading promotion of nonapproved GLP-1 compounds as equivalents. The compounding guide distinguishes permissible pharmacy compounding circumstances from approval claims, while the generic status page explains how to verify any future approved entry.
Semaglutide brands sold legally in India may have approval there without an FDA-approved U.S. NDA or ANDA for that specific product. A seller cannot establish U.S. approval by pointing to an Indian manufacturer or the semaglutide ingredient alone. Importation rules and product-quality risks are separate questions.
The Indian brands directory identifies regional products and manufacturers for comparison, not a U.S. purchase catalog. Check the imported-products guide before trusting an overseas listing as an FDA-approved supply.
A seller may advertise the name of a genuinely approved brand while offering a counterfeit, diverted or misrepresented package. FDA has reported counterfeit Ozempic in the U.S. supply chain. An official approval directory cannot verify an individual seller’s inventory or guarantee a parcel is authentic.
Use product-integrity red flags and legitimate online pharmacy signs before trusting an unfamiliar merchant, especially one offering prescription-free delivery.
A useful audit trail contains four independent facts: the FDA-approved brand and presentation; the application or supplement and most recent label; a valid prescription naming the same product; and the licensed pharmacy that will dispense it. A medication identified only as “semaglutide,” without its approved form and strength, does not complete this check.
Regulatory status reviewed against the U.S. FDA product record framework as of October 18, 2026. This site is an independent informational resource, not a regulator or pharmacy. If a commercial outbound link is compensated, that relationship should be disclosed near the referral.
Ozempic and Wegovy have FDA-approved U.S. presentations; Rybelsus remains relevant as a legacy approved oral brand subject to a 2026 shipment phase-out.
No. Wegovy HD is a distinct 7.2-mg injection presentation with defined adult labeling; the pill is an oral product.
No. Approval records, active marketing and individual pharmacy inventory are different questions.
Not necessarily. Each presentation has specific FDA labeling that should be checked separately.
Not by itself. Verify the product and its NDA or ANDA through official FDA resources.
No. Approval in another country does not establish approval for that particular product in the United States.
No. Compounded drugs are not FDA-approved products and should not be advertised as approved equivalents.
Its historical approval and product information remain relevant even when its marketing and wholesale distribution change.
Search the FDA-approved drug and Orange Book records for the exact drug product, application, dosage form and approval status.